Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
Biogen (BIIB) beat estimates for earnings but marginally misses the same for sales in Q1. The company's oral MS drug Tecfidera sales increased year over year.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Novartis (NVS) Reports Encouraging Data on MS Candidate
by Zacks Equity Research
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
by Zacks Equity Research
Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis
by Zacks Equity Research
Novartis (NVS) signs a contract to purhcase the U.S. based clinical stage gene therapy company, AveXis, Inc for a cash-tender offer of $218 per share.
Biogen Cracks the Case With AbbVie for Humira Biosimilar
by Zacks Equity Research
Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Why Multiple Sclerosis is a Promising but Risky Space?
by Zacks Equity Research
Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.
Are Alzheimer's-Focused Stocks Set for a Financial Windfall?
by Zacks Equity Research
Launch of the blood tests will help companies focused on developing preventive treatments make billions.
Biogen (BIIB) Down 17.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.